       Document 0905
 DOCN  M9620905
 TI    HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response
       in human subjects and preliminary evidence of protection against HIV
       challenge in SCID mice.
 DT    9602
 AU    Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine
       P; Gazzard B; Youle M; Rios A; et al; Department of Biochemistry and
       Molecular Biology, George; Washington University Medical Center,
       Washington, D.C. 20037,; USA.
 SO    Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):401-7. Unique Identifier
       : AIDSLINE MED/96059401
 AB    An HIV-1 p17 subunit vaccine, HGP-30, was evaluated in 38 HIV-1
       seronegative individuals in phase I clinical trials in U.K. and U.S.A.
       The vaccine preparation induced cytotoxic T-cell (CTL) (11/25) and
       lymphocyte proliferation responses to KLH (19/20) and HGP-30/p17 (24/29)
       as well as antibody responses to HGP-30 (29/38) and KLH (38/38). The CTL
       activity was observed in a higher number of vaccine recipients (9/18) in
       the lower dose groups (10 and 25 micrograms/kg) than the vaccine
       recipients (2/7) in the 50 and 100 micrograms/kg dose group. These
       observations suggest that the 10-25 micrograms/kg vaccine dose may
       preferentially induce TH1 cell responses. TH1 cell responses have been
       suggested as important in inducing protective cell mediated immunity.
       The CTL response has been shown to be CD8+. In a pilot study in SCID
       mice, HIV-1 virus challenge studies in mice reconstituted with cells
       from an HGP-30 immunized individual showed protection against virus
       challenge as compared to SCID mice reconstituted with cells from a
       non-immunized subject. These studies suggest that HGP-30 is capable of
       inducing protective cellular immunity.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL  Amino Acid
       Sequence  Animal  AIDS Vaccines/*IMMUNOLOGY  Cytotoxicity, Immunologic
       Female  Human  HIV Antibodies/*BIOSYNTHESIS  HIV Antigens/*IMMUNOLOGY
       HIV-1/IMMUNOLOGY  Immunization, Passive  Immunodominant
       Epitopes/IMMUNOLOGY  Lymphocyte Transformation  Male  Mice  Mice, SCID
       Molecular Sequence Data  Peptides/*IMMUNOLOGY  Pilot Projects  Support,
       Non-U.S. Gov't  *Vaccination  Vaccines, Synthetic/ADMINISTRATION &
       DOSAGE/IMMUNOLOGY  CLINICAL TRIAL  CLINICAL TRIAL, PHASE I  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

